IKNA Ikena Oncology Inc.

10.43
-0.73  -7%
Previous Close 11.16
Open 11.25
52 Week Low 9.63
52 Week High 37.61
Market Cap $438,837,922
Shares 42,074,585
Float 29,922,440
Enterprise Value $228,277,218
Volume 38,960
Av. Daily Volume 81,460
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
IK-175 and OPDIVO (nivolumab)
Bladder cancer
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
IK-007 and KEYTRUDA (pembrolizumab)
Colorectal cancer
Phase 1b
Phase 1b
Phase 1b enrollment to be completed 2H 2022.

Latest News

    • Meeting, taking place October 7-10, 2021, is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC)
    • Data presented indicates NF2-deficient mesothelioma and other cancers harboring mutations in the Hippo signal transduction pathway as promising indications for clinical development of Ikena's novel TEAD inhibitor, IK-930
    • Research supports substantial opportunity for combining TEAD inhibitors with EGFR and MEK inhibitors in the treatment of EGFR and KRAS mutated cancers

    BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company navigating new territory in patient-directed…

    • Meeting, taking place October 7-10, 2021, is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC)

    • Data presented indicates NF2-deficient mesothelioma and other cancers harboring mutations in the Hippo signal transduction pathway as promising indications for clinical development of Ikena's novel TEAD inhibitor, IK-930
    • Research supports substantial opportunity for combining TEAD inhibitors with EGFR and MEK inhibitors in the treatment of EGFR and KRAS mutated cancers

    BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that the Company will present two virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10, 2021. Both presentations highlight the potential of inhibitors of the transcription factor TEAD, a key mediator of Hippo pathway signaling, in cancer treatment.

    Ikena's lead TEAD inhibitor candidate, IK-930, is designed to bind to and disrupt TEAD-dependent transcription for treating multiple difficult-to-treat tumor types harboring mutations in the Hippo pathway. The conference presentations will highlight the Hippo pathway and TEAD's role in tumor growth and therapeutic resistance, and IK-930's potential as a monotherapy and in combination with EGFR and MEK inhibitors.

    "Our thorough understanding of disrupted Hippo pathway signaling provides insights into monotherapy opportunities for IK-930 in cancer patients. Moreover, the compensatory survival role the Hippo pathway plays upon inhibition of other oncogenic signaling pathways enables use of IK-930 as part of a broader treatment regimen to overcome therapeutic resistance," said Jeffrey Ecsedy, Ph.D., Ikena's Chief Scientific Officer. "The data we are sharing at this year's conference are prime examples of how we want to interrogate TEAD as a target and IK-930 as a therapy. These data support the potential for IK-930 as a monotherapy in indications like NF2-mutant mesothelioma, show how patient selection will be key to successful outcomes and highlight ways we can incorporate combination strategies early in the development of IK-930."

    Marta Sanchez-Martin, Ph.D., Principal Scientist, Translational Research, at Ikena, will discuss how the Company used a systems biology approach, integrating genomic, transcriptional, tissue-based and pharmacological profiling to identify NF2-deficient mesothelioma as the most relevant indication for clinical development of Ikena's TEAD inhibitor as a monotherapy. A unique comprehensive set of bioinformatic and proprietary immunohistochemical analyses identified additional clinical opportunities for TEAD inhibitors as a monotherapy and in combination with other agents for a variety of cancer types, including non-small cell lung cancer (NSCLC) and soft tissue sarcoma, and supports a biomarker-driven approach for identifying ideal combination treatments leveraging TEAD inhibitors.

    Data presented by Ben Amidon, Ph.D., Senior Director of Biology at Ikena, further supports the potential of IK-930 as a potent and selective TEAD inhibitor, both as a monotherapy in mesothelioma, and in combination with other agents in NSCLC and CRC. IK-930 showed promise as a single agent both in vitro and in vivo in Hippo dysregulated mesothelioma and further potential when combined with EGFR and MEK inhibitors in KRAS mutant cancers, including lung and colon cancer, enhancing apoptosis and anti-tumor activity.

    Full presentations will be available on-demand as part of the conference from October 7-10. Details are as follows:

    Poster #1

    • Title: Systems biology-guided indication selection to inform the clinical development of a novel TEAD inhibitor
    • Presenter: Marta Sanchez-Martin, Ph.D., Principal Scientist, Translational Research

    Poster #2

    • Title: IK-930 mediated TEAD inhibition decreases and delays tumor growth and enhances targeted apoptosis in lung and colon cancer xenografts when combined with MEK or EGFR inhibitors
    • Presenter: Ben Amidon, Ph.D., Senior Director, Biology

    Both presentation recordings will be available on-demand throughout the conference. Register to participate and view here. The recordings can be accessed by visiting the Investors & Media section of the company's website at www.ikenaoncology.com.

    About Ikena Oncology

    Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company's lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb, including IK-175, an aryl hydrocarbon receptor antagonist designed to modulate the tumor microenvironment. Ikena's pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

    Media Contact:

    Gwen Schanker

    LifeSci Communications

    gschanker@lifescicomms.com



    Investor Contact:

    Rebecca Cohen

    Ikena Oncology

    rcohen@ikenaoncology.com



    Primary Logo

    View Full Article Hide Full Article
  1. BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, with novel inhibitor IK-175, will be presented at the SITC 2021 Annual Meeting. IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment to increase both innate and adaptive immunity and is currently being studied in a Phase 1 clinical trial.

    Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) is being held in-person and virtually November 10-14, 2021. Abstract details can be found below…

    BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, with novel inhibitor IK-175, will be presented at the SITC 2021 Annual Meeting. IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment to increase both innate and adaptive immunity and is currently being studied in a Phase 1 clinical trial.

    Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) is being held in-person and virtually November 10-14, 2021. Abstract details can be found below.         

    Aryl Hydrocarbon Receptor (AHR) Antagonist Program

    Title: A Phase 1a/b Study of IK-175, an Oral AHR Inhibitor, Alone and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

    Abstract Number: 392

    Presenter:  Jason Luke MD, FACP, Trial Investigator, UPMC Hillman Cancer Center

    Title: Computational biology and tissue-based approaches to inform indication selection for a novel AHR inhibitor

    Abstract Number: 93

    Presenter: Marta Sanchez-Martin, PhD, Ikena Oncology

    Title: Analytical validation of a novel immunohistochemistry assay to determine nuclear AHR expression in human bladder cancer

    Abstract Number: 58

    Presenter: Lei Wang, PhD, Ikena Oncology

    The Phase 1 trial of IK-175 is currently recruiting in both monotherapy and combination arm in advanced solid tumors and recently expanded its monotherapy urothelial carcinoma cohort. For more information on the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and how to register, visit the website.

    About Ikena Oncology

    Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company's lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb, including IK-175, an aryl hydrocarbon receptor antagonist designed to modulate the tumor microenvironment. Ikena's pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

    Media Contact:

    Gwen Schanker

    LifeSci Communications

    gschanker@lifescicomms.com



    Investor Contact:

    Rebecca Cohen

    Ikena Oncology

    rcohen@ikenaoncology.com 



    Primary Logo

    View Full Article Hide Full Article
  2. BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference taking place on September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, taking place on September 13-15, 2021.

    Details are as follows:

    Conference: Morgan Stanley 19th Annual Global Healthcare Conference
    Fireside Chat: Friday, September 10, 2021, 10:15am EST; live and available for replay        
    Webcast Link

    Conference: H.C. Wainwright 23rd Annual Global Investment Conference
    Date: Monday, September 13, 2021…

    BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference taking place on September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, taking place on September 13-15, 2021.

    Details are as follows:

    Conference: Morgan Stanley 19th Annual Global Healthcare Conference

    Fireside Chat: Friday, September 10, 2021, 10:15am EST; live and available for replay        

    Webcast Link

    Conference: H.C. Wainwright 23rd Annual Global Investment Conference

    Date: Monday, September 13, 2021; available for replay        

    Webcast Link

    The presentation webcasts can be accessed by visiting the Investors & Media section of the company's website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.

    About Ikena Oncology

    Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing multiple programs that target tumor markers as well as programs targeting the tumor microenvironment. The Company's lead program, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway, a pathway that can drive formation and increase survival of tumors and also drives development of resistance to multiple existing therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and several programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb. Ikena's pipeline is built on targeting genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

    Media Contact:

    Gwen Schanker

    LifeSci Communications

    gschanker@lifescicomms.com



    Investor Contact:

    Rebecca Cohen

    Ikena Oncology

    rcohen@ikenaoncology.com

     



    Primary Logo

    View Full Article Hide Full Article
  3. IK-930 IND on track for submission in 2021; multiple upcoming preclinical and translational conference presentations on TEAD inhibition by IK-930

    Progressing IK-175 clinical trial monotherapy expansion cohort in bladder cancer patients

    Continued progress across targeted oncology pipeline towards research and clinical milestones

    BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced financial results for the quarter that ended June 30, 2021. The Company also shared updates on several pipeline programs targeting tumor signaling pathways, including Hippo, RAS, and the tumor…

    IK-930 IND on track for submission in 2021; multiple upcoming preclinical and translational conference presentations on TEAD inhibition by IK-930

    Progressing IK-175 clinical trial monotherapy expansion cohort in bladder cancer patients

    Continued progress across targeted oncology pipeline towards research and clinical milestones

    BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced financial results for the quarter that ended June 30, 2021. The Company also shared updates on several pipeline programs targeting tumor signaling pathways, including Hippo, RAS, and the tumor microenvironment.

    "In recent months, the Ikena team has continued to generate data on the important targets we are exploring and our development candidates. This work has further elucidated the potential of TEAD inhibition as a monotherapy and in combination with other targeted therapies, and enables us to further refine the clinical development strategy for IK-930, our novel TEAD inhibitor," said Mark Manfredi, PhD, Chief Executive Officer of Ikena Oncology. "We look forward to sharing these and more updates as our data matures and we make strides towards our goal to transform the landscape of cancer treatment to a targeted, patient-focused treatment paradigm."

    Ikena is also evaluating our novel AHR antagonist, IK-175, in a Phase I clinical trial as a monotherapy and in combination with nivolumab for the treatment of advanced or metastatic solid tumors, including in urothelial carcinoma, a type of bladder cancer where there is a significant unmet need. After completing the monotherapy dose escalation we are progressing the expansion cohort and enrolling additional urothelial carcinoma patients to continue evaluating IK-175 as a monotherapy and the path towards proof-of-concept in this patient population.

    "The emerging clinical data observed for IK-175 monotherapy in urothelial carcinoma and the expansion of the cohort are great steps toward establishing proof of concept. These patients have very limited options for treatment, and we are hopeful that IK-175 could have significant impact in this setting," said Sergio Santillana, MD, Chief Medical Officer at Ikena. "The monotherapy cohort expansion is an encouraging development for the Ikena team and ultimately for the patients whose cancer could be treated with this novel therapy. We look forward to generating additional data and providing an update on safety and preliminary anti-tumor activity of IK-175 at a medical conference in 2022."  

    Recent Pipeline Progress and Corporate Update

    • IK-930: TEAD Inhibitor in the Hippo Signaling Pathway in IND-enabling Studies
      • IND-enabling studies continued to progress and the IND submission is on track for the end of 2021.
      • Translational and preclinical data will be shared at the EORTC-NCI-AACR 2021 Virtual International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10, 2021.

        • Virtual Poster Presentation of IK-930 indication selection methodology and data, highlighting a novel method to assess activation across the Hippo pathway and the rationale behind mesothelioma as a cancer type that could benefit from TEAD inhibition as a monotherapy
        • Virtual Poster Presentation of the tumor growth inhibition observed in in vivo preclinical models of lung and colon cancer with IK-930 combined with inhibition of MEK and EGFR, separately and in triplet
    • IK-175:  Clinical Stage AHR Antagonist Partnered with Bristol Myers Squibb (BMS)
      • Ikena is expanding the monotherapy bladder cancer cohort to treat additional patients in the current dose expansion cohort per protocol of the ongoing Phase 1 clinical trial.
      • Translational and preclinical data will be shared at scientific conferences in the second half of 2021.
      • Clinical data presentation planned for a major medical conference in 2022.
    • IK-412: Novel Enzymatic Therapeutic Degrading Kynurenine Partnered with BMS
      • Ikena was notified in the second quarter that a key component required in the manufacturing of IK-412 is also required for the manufacturing of COVID-19 vaccines and therapies. As a result, the availability of the component for purposes other than vaccine production is extremely limited in the near-term.
        • This situation impacted our manufacturing lead times, delaying the planned IND submission for IK-412.
        • Updated guidance on IND submission timing will be provided when material supply of this key component can be reliably projected.
        • We continue to work closely with our supplier and contract manufacturing organization, as well as our partner BMS, to advance the program toward IND submission.
      • IND-enabling studies of IK-412 continue to progress as planned.
    • Additional Pipeline Programs Continue to Progress

    Financial Results for the Quarter Ended June 30, 2021

    As of June 30, 2021, the Company had cash and cash equivalents totaling $264.0 million, which will fund operations through 2023. Net cash used in operations was $15.7 million for the second quarter of 2021 as compared to $7.7 million for the second quarter of 2020.

    Research and development expenses for the second quarter 2021 were $11.4 million, compared to $6.3 million for the second quarter 2020. The increase in R&D expense was primarily related to on-going IND-enabling studies and manufacturing development costs for IK-930, ongoing IND-enabling studies for IK-412, increased research activities of other discovery stage programs and increased personnel expenses due to increase in headcount. The increase in research and development expenses was offset by a decrease in expense attributable to drug manufacturing of IK-175 and a decrease in clinical activities for IK-007.

    General and administrative expenses for the second quarter were $4.9 million, compared to $1.8 million for the second quarter 2020. The increase in G&A expense was primarily related to compensation expense due to an increase in headcount, as well as general increases in audit, legal and consulting expenses to support our operations as a public company.

    Net loss for the second quarter 2021 was $12.7 million, compared to $5.0 million for the second quarter 2020, driven by increases in research and development and general and administrative expenses.

    About Ikena Oncology

    Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing multiple programs that target tumor markers as well as programs targeting the tumor microenvironment. The Company's lead program, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway, a pathway that can drive formation and increase survival of tumors and also drives development of resistance to multiple existing therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and several programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb. Ikena's pipeline is built on targeting genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding: the timing and advancement of our targeted oncology programs; our expectations regarding the therapeutic benefit of our targeted oncology programs; expectations regarding the timing of the expansion of the monotherapy cohort for IK-175; the future availability of key components in the manufacture of IK-412; our expectations regarding delays in our clinical trials, including for IK-412; our expectations regarding the progression of our preclinical studies, including IND-enabling studies for IK-412; our expectations regarding the timing of presentation of preclinical and clinical data; our ability to efficiently discover and develop product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the implementation of our business model, and strategic plans for our business and product candidates. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to: the timing and advancement of our targeted oncology programs; our ability to demonstrate the therapeutic benefit of our targeted oncology programs; our ability to efficiently discover and develop product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the implementation of our business model, and strategic plans for our business and product candidates: and other risks identified in our SEC filings, including our Registration Statement on Form S-1, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made and should not be relied on as representing our views as of any subsequent date. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

     
    Condensed Consolidated Balance Sheet Data

    (Unaudited)

    (in thousands)

             
      June 30,

    2021
      December 31,

    2020
     
    Cash and cash equivalents $264,004  $162,491 
    Total assets  278,827   168,404 
    Total liabilities  62,567   63,473 
    Redeemable convertible preferred stock  -   205,979 
    Additional paid-in-capital  349,960   10,288 
    Accumulated deficit  (133,736)  (111,339)
    Total stockholders' equity (deficit)  216,260   (101,048)
             



     
    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (Unaudited)

    (in thousands)

                     
      Three Months Ended June 30,  Six Months Ended June 30, 
      2021  2020  2021  2020 
    Research and development revenue under collaboration agreement $3,549  $3,073  $7,023  $6,300 
    Operating expenses:                
    Research and development  11,374   6,334   21,396   14,226 
    General and administrative  4,862   1,798   8,035   4,308 
    Total operating expenses  16,236   8,132   29,431   18,534 
    Loss from operations  (12,687)  (5,059)  (22,408)  (12,234)
    Other income (expense), net  6   21   11   251 
    Net loss and comprehensive loss $(12,681) $(5,038) $(22,397) $(11,983)
    Net loss per share attributable to common stockholders basic and diluted $(0.35) $(1.89) $(1.12) $(4.51)
    Weighted-average common stocks outstanding, basic and diluted  35,853,341   2,658,800   19,940,204   2,657,283 
                     

    Media Contact:

    Gwen Schanker

    LifeSci Communications

    gschanker@lifescicomms.com

    Investor Contact:

    Rebecca Cohen

    Ikena Oncology

    rcohen@ikenaoncology.com



    Primary Logo

    View Full Article Hide Full Article
  4. BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Mark Manfredi, CEO of Ikena Oncology, will participate in a panel discussing next-generation approaches to targeted oncology at the upcoming virtual William Blair Biotech Focus Conference.

    Details on the panel webcast can be found below.

            Date: Thursday, July 15, 2021
            Time: 9:00 – 9:45 a.m. ET
            Webcast Link: Register

    The panel will be webcast live and can be accessed by visiting the Investors & Media section of the company's website at www.ikenaoncology.com. The webcast will be…

    BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Mark Manfredi, CEO of Ikena Oncology, will participate in a panel discussing next-generation approaches to targeted oncology at the upcoming virtual William Blair Biotech Focus Conference.

    Details on the panel webcast can be found below.

            Date: Thursday, July 15, 2021

            Time: 9:00 – 9:45 a.m. ET

            Webcast Link: Register

    The panel will be webcast live and can be accessed by visiting the Investors & Media section of the company's website at www.ikenaoncology.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

    About Ikena Oncology

    Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs. To learn more visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

    Media Contact:

    Gwen Schanker

    LifeSci Communications

    gschanker@lifescicomms.com



    Investor Contact:

    Rebecca Cohen

    Ikena Oncology

    rcohen@ikenaoncology.com



    View Full Article Hide Full Article
View All Ikena Oncology Inc. News